Clinical trial · Interventional
Combination Chemotherapy in Treating Patients With Sarcoma
A Pilot Study for Soft Tissue Sarcoma
NCT00662233CI-TRIAL-00035180completedEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This clinical trial is studying how well combination chemotherapy works in treating patients with sarcoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
| Sarcoma | Sarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (11)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| adjuvant therapy | Procedure | — | UNRESOLVED |
| brachytherapy | Radiation | — | UNRESOLVED |
| cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| doxorubicin hydrochloride | Drug | Doxorubicin | ALIAS |
| etoposide | Drug | Etoposide | ALIAS |
| ifosfamide | Drug | Ifosfamide | ALIAS |
| intraoperative radiation therapy | Radiation | — | UNRESOLVED |
| neoadjuvant therapy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Efficacy in terms of long-term disease-free survival
- measure
- Clinical response of the tumors
- measure
- Pathologic response of the tumors
- measure
- Long term disease-free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 21 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of any of the following: * High-grade nonmetastatic, nonrhabdomyosarcomatous soft tissue sarcomas (excluding undifferentiated sarcoma and Ewing sarcoma) * Small round cell sarcomas (excluding primitive neuroectodermal tumors of soft tissue) (closed to accrual) * Undifferentiated sarcomas (closed to accrual) * Rhabdomyosarcomas (excluding non-parameningeal head tumors, vaginal or stage I paratesticular) (closed to accrual) * All alveolar rhabdomyosarcomas (closed to accrual) * No evidence distant metastatic disease (i.e., lung, bone, bone marrow) * Local or regional nodal disease allowed * No spindle cell tumors of bone * Primary lesions do not have to be resectable PATIENT CHARACTERISTICS: * Creatinine ≤1.5 mg/dL OR creatinine clearance \> 60 mL/min/ * AST/ALT \< 2 times upper limit of normal (ULN) * Total bilirubin \< 2 times ULN * LVEF ≥ 45% * No prior history of cancer * Not pregnant or nursing * Negative pregnancy test PRIOR CONCURRENT THERAPY: * Patients who have undergone radiation therapy after initial surgery are eligible but must have evaluation for metastatic disease within 2 weeks of starting chemotherapy * No prior chemotherapy
References
Publications (0)
Data not yet available
No reference posted for this study.